

Filed: December 10, 2014

Filed on behalf of:

Mylan Pharmaceuticals Inc.

By: Joseph M. Reisman
Jay R. Deshmukh

KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, CA 92614
Ph.: (949) 760-0404 Fax: (949) 760-9502
E-mail: BoxMylan@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
Patent Owners

Case No. IPR2015-00265
Patent 6,316,023

MYLAN EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioner Mylan Pharmaceuticals Inc. (“Mylan”) hereby provides a current list of its exhibits filed thus far in this case.

MYLAN EXHIBIT LIST

Exhibit No.	Description
Ex. 1001	U.S. Patent No. 6,316,023, issued November 13, 2001
Ex. 1002	UK Patent Application GB 2,203,040 A, to Enz, published October 12, 1988 (“Enz”)
Ex. 1003	Handbook of Pharmaceutical Excipients, A. Wade and P. J. Weller (eds.) 1994, 2 nd Edition, The Pharmaceutical Press London (the “Handbook”)
Ex. 1004	Japanese Patent Application Publication No. JP 59-184121 to Sasaki et al., published October 19, 1984
Ex. 1005	Certified English Translation of Japanese Patent Application Publication No. JP 59-184121 to Sasaki et al. (“Sasaki”)
Ex. 1006	PCT Publication No. WO 95/024172 to Ebert et al, published September 14, 1995 (“Ebert”)
Ex. 1007	European Patent Application No. 0155 229 A2 to Kissel et al., published September 18, 1985 (“Kissel”)
Ex. 1008	U.S. Patent No. 4,948,807 (“Rosin”)
Ex. 1009	Elmalem et al. 1991, Neuropharmacology 30: 1059-1064 (“Elmalem”)
Ex. 1010	Declaration of Agis Kydonieus, Ph.D.

Exhibit No.	Description
Ex. 1011	Declaration of Christian Schöneich, Ph.D.
Ex. 1012	“Safety/Tolerability Trial of SDZ ENA 713 in Patients with Probable Alzheimer’s Disease,” John J. Sramek et al., Life Sciences, Vol. 58, No. 15, pp. 1201-1207 (1996) (“Sramek”)
Ex. 1013	“New acetylcholinesterase inhibitor shows promise in largest Alzheimer’s trial to date,” Formulary, Vol. 32, Dec. 1997 (“Formulary Article”)
Ex. 1014	ICH Topic Q 1 A, Stability Testing Guidelines: Stability Testing of New Drug Substances and Products (CPMP/ICH/380/95)
Ex. 1015	Connors, Amidon, & Stella, Oxidation and Photolysis in Chemical Stability of Pharmaceuticals – A Handbook for Pharmacists (2nd Edition), John Wiley & Sons, NY (1986), pp. 82-114
Ex. 1016	Howard C. Ansel, Introduction to Pharmaceutical Dosage Forms, 4th Edition, Lea & Febiger, Philadelphia (1985), pp. 83-116
Ex. 1017	Ho-Leung Fung, Chapter 7 – Chemical Kinetics and Drug Stability in MODERN PHARMACEUTICS (G.S. Banker and C.T. Rhodes, eds.), Marcel Dekker, NY (1978), pp. 227-62
Ex. 1018	Carey & Sundberg, ADVANCED ORGANIC CHEMISTRY, 2nd ed. Part A: Structure and Mechanism, Plenum Press, New York, 1984, pp. 652
Ex. 1019	Miguel-Hidalgo, J., 2000, Current Opinion in CPNS Investigations Drugs, 2000 2(4):438-453

Exhibit No.	Description
Ex. 1020	Boccardi G. et al. Photochemical Iron(III)-Mediated Autoxidation of Dextromethorphan. Chemical & Pharmaceutical Bulletin. Vol. 37, 308-310 (1989)
Ex. 1021	Bateman, L., Olefin Oxidation, Quarterly Review (1954) Vol. 8, pp. 147-167
Ex. 1022	Linnell, R.H., The Oxidation of Nicotine. I. Kinetics of the Liquid Phase Reaction Near Room Temperature. Tobacco Science, Vol. 4, pp. 89-90 (1960)
Ex. 1023	Resume/ Curriculum Vitae of Agis Kydonieus, Ph.D.
Ex. 1024	Resume/ Curriculum Vitae of Christian Schöneich, Ph.D.
Ex. 1025	U.S. Patent No. 5,602,176, issued Feb. 11, 1997
Ex. 1026	Declaration of William R. Zimmerman in Support of Motion to Appear Pro Hac Vice on Behalf of petitioner Mylan Pharmaceuticals Inc.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 10, 2014

By: _____



Joseph M. Reisman

Reg. No. 43,878
Customer No. 20,995

Attorneys for Petitioner
MYLAN PHARMACEUTICALS INC.
(949) 760-0404

IPR2015-00265
Mylan v. Novartis


CERTIFICATE OF SERVICE

I hereby certify that a true and correct copy of the foregoing **MYLAN EXHIBIT LIST** is being served on December 10, 2014, via email pursuant to 37 C.F.R. § 42.6(e) per agreement of the parties, to counsel for Novartis AG and LTS Lohmann Therapie-Systeme AG at the address below:

ExelonPatchIPR@fchs.com

Raymond R. Mandra
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104

Dated: December 10, 2014



Joseph M. Reisman, Reg. No. 43,878
Attorney for Petitioner
Mylan Pharmaceuticals Inc.

19436390